Irritable Bowel Syndrome Drugs Market: By Condition (Irritable Bowel Syndrome for Constipation, Irritable Bowel Syndrome for Diarrhea, Others), By Drugs (Alosetron, Rifaximin, Eluxadoline, Linaclotide, Lubiprostone, Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Irritable bowel syndrome Market size was valued at USD 1.5 billion in 2022 and is poised to grow at a significant CAGR of 10.1% from 2023-2029.Gastrointestinal tract disorder characterized by stomach pain and alteration bowel habits. It hampers the regular development of intestinal muscle linings to move food along the tract. Based on the manifestations, the disorder can be mild to severe irritable bowel syndrome. The symptoms may include cramping, stomach torment, swelling and gas, mucus in the stool, constipation, and loose bowels. The exact reason for irritable bowel disease is not known however, it is related with increased awareness of body function, and unusual gastrointestinal tract movements. The diagnostic is performed by testing the stool and blood. Endoscopic procedures are also used in diagnosis of the syndrome. For instance, in March 2017, Astellas Pharma Inc. has launched LINZESS tablets, a guanylate cyclase receptor agonist to treat irritable bowel syndrome with constipation into Japan market. Europe market anticipated to have the notable growth rate owing to presence of the major market players and active development of drugs to treat the irritable bowel syndrome.

Global Irritable Bowel Syndrome Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

10.1%

Largest Market

North America

Fastest Growing Market

Asia-Pacific
Irritable Bowel Syndrome Drugs Market Dynamics

Global irritable bowel syndrome is primarily driven by the increase in prevalence of the syndrome worldwide. In addition robust pipeline of drugs such as alizyme, ramosetron and activity of the market players including product launches and collaborations projected to boost the market growth over the forecast period. Furthermore, change in the lifestyles, increased stress and favorable reimbursement policies in treatment of the disease projected to bolster the market share. Moreover, developments healthcare diagnostic sector in identifying the underlying disease and better understanding of pathology of disease projected to positively impact the development of new drug treatments. However, high cost of development and stringent regulatory policies are expected to hamper the market growth over the forecast period.

Global Irritable Bowel Syndrome Drugs Market Segmentation

By Condition
  • Irritable Bowel Syndrome - Constipation
  • Irritable Bowel Syndrome - Diarrhea
  • Others
By Drug
  • Alosetron
  • Eluxadoline
  • Linaclotide
  • Lubiprostone
  • Others
By Distribution Channel
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
By Geography

North America

  • US
  • Canada

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

Asia-Pacific

  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

Frequently Asked Questions

The key segments covered in the Irritable Bowel Syndrome Drugs Market are technology, components, application, and end-users.

The Irritable Bowel Syndrome Drugs Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

The Irritable Bowel Syndrome Drugs Market key players are Allergan Plc. (Ireland), Lexicon Pharmaceuticals, Inc. (U.S.), Sucampo Pharmaceuticals (U.S.), Astellas Pharma Inc., Pfizer Inc. (U.S.), Novartis AG (Switzerland), Ironwood Pharmaceuticals, Inc. (U.S.), Synergy Pharmaceuticals (U.S.), Ono Pharmaceutical Co., Ltd. (Japan), Abbot Laboratories. (U.S.), Takeda Pharmaceutical Company Ltd. (Japan)

Key Features of the Reports

  • In April 2017, Takeda Pharmaceutical Company Limited and Finch Therapeutics has entered into the collaboration agreement to develop the microbiome therapeutics in inflammatory bowel disease
1.Executive Summary
2.Global Irritable Bowel Syndrome Drugs Market Introduction 
2.1.Global Irritable Bowel Syndrome Drugs Market  - Taxonomy
2.2.Global Irritable Bowel Syndrome Drugs Market  - Definitions
2.2.1.Condition
2.2.2.Drug
2.2.3.Distribution Channel
2.2.4.Region
3.Global Irritable Bowel Syndrome Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Irritable Bowel Syndrome Drugs Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Irritable Bowel Syndrome Drugs Market  By Condition, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Irritable Bowel Syndrome - Constipation
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Irritable Bowel Syndrome - Diarrhea
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Others
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6.Global Irritable Bowel Syndrome Drugs Market  By Drug, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Alosetron
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Eluxadoline
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Linaclotide
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Lubiprostone
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Irritable Bowel Syndrome Drugs Market  By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Retail Pharmacies
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Online Pharmacies
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Hospital Pharmacies
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Irritable Bowel Syndrome Drugs Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Irritable Bowel Syndrome Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Condition Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Irritable Bowel Syndrome - Constipation
9.1.2.Irritable Bowel Syndrome - Diarrhea
9.1.3.Others
9.2.  Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Alosetron
9.2.2.Eluxadoline
9.2.3.Linaclotide
9.2.4.Lubiprostone
9.2.5.Others
9.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Retail Pharmacies
9.3.2.Online Pharmacies
9.3.3.Hospital Pharmacies
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Irritable Bowel Syndrome Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Condition Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Irritable Bowel Syndrome - Constipation
10.1.2.Irritable Bowel Syndrome - Diarrhea
10.1.3.Others
10.2.  Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Alosetron
10.2.2.Eluxadoline
10.2.3.Linaclotide
10.2.4.Lubiprostone
10.2.5.Others
10.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Retail Pharmacies
10.3.2.Online Pharmacies
10.3.3.Hospital Pharmacies
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) Irritable Bowel Syndrome Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Condition Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Irritable Bowel Syndrome - Constipation
11.1.2.Irritable Bowel Syndrome - Diarrhea
11.1.3.Others
11.2.  Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Alosetron
11.2.2.Eluxadoline
11.2.3.Linaclotide
11.2.4.Lubiprostone
11.2.5.Others
11.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Retail Pharmacies
11.3.2.Online Pharmacies
11.3.3.Hospital Pharmacies
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Irritable Bowel Syndrome Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Condition Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Irritable Bowel Syndrome - Constipation
12.1.2.Irritable Bowel Syndrome - Diarrhea
12.1.3.Others
12.2.  Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Alosetron
12.2.2.Eluxadoline
12.2.3.Linaclotide
12.2.4.Lubiprostone
12.2.5.Others
12.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Retail Pharmacies
12.3.2.Online Pharmacies
12.3.3.Hospital Pharmacies
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Irritable Bowel Syndrome Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Condition Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Irritable Bowel Syndrome - Constipation
13.1.2.Irritable Bowel Syndrome - Diarrhea
13.1.3.Others
13.2.  Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Alosetron
13.2.2.Eluxadoline
13.2.3.Linaclotide
13.2.4.Lubiprostone
13.2.5.Others
13.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Retail Pharmacies
13.3.2.Online Pharmacies
13.3.3.Hospital Pharmacies
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Allergan Plc. (Ireland)
14.2.2.Lexicon Pharmaceuticals, Inc. (U.S.)
14.2.3.Sucampo Pharmaceuticals (U.S.)
14.2.4.Astellas Pharma Inc.
14.2.5.Pfizer Inc. (U.S.)
14.2.6.Novartis AG (Switzerland)
14.2.7.Ironwood Pharmaceuticals, Inc. (U.S.)
14.2.8.Synergy Pharmaceuticals (U.S.)
14.2.9.Ono Pharmaceutical Co., Ltd. (Japan)
14.2.10.Abbot Laboratories. (U.S.)
14.2.11.Takeda Pharmaceutical Company Ltd. (Japan)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Allergan Plc. (Ireland)
  • Lexicon Pharmaceuticals, Inc. (U.S.)
  • Sucampo Pharmaceuticals (U.S.)
  • Astellas Pharma Inc.
  • Pfizer Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Ironwood Pharmaceuticals, Inc. (U.S.)
  • Synergy Pharmaceuticals (U.S.)
  • Ono Pharmaceutical Co., Ltd. (Japan)
  • Abbot Laboratories. (U.S.)
  • Takeda Pharmaceutical Company Ltd. (Japan)

Adjacent Markets